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Summary
Background Biologics targeting inflammatory mediators can achieve clinical
improvements in hidradenitis suppurativa (HS). However, their clinical efficacy
shows great interpatient variability in daily practice.
Objectives To investigate the anti-inflammatory potency of a selection of currently
available biologics and prednisolone for the treatment of HS in an ex vivo skin cul-
ture system using lesional HS biopsies.
Methods Lesional skin samples from 10 patients with HS and skin samples from
five healthy controls were cultured ex vivo and exposed to prednisolone or biolog-
ics targeting tumour necrosis factor (TNF)-a, interleukin (IL)-17A, IL-12/23p40
or CD20 (adalimumab, infliximab, secukinumab, ustekinumab and rituximab,
respectively). Real-time quantitative polymerase chain reaction and cytokine bead
arrays were used to measure the inhibitory effect of the biologics on cytokines
and antimicrobial peptides (AMPs).
Results The relative mRNA expression of all tested cytokines and AMPs was signifi-
cantly downregulated by all anti-inflammatory agents (P < 0001). The protein
production of the proinflammatory cytokines TNF-a, interferon c, IL-1b, IL-6 and
IL-17A was significantly inhibited by adalimumab, infliximab, ustekinumab, pred-
nisolone (all P < 0001) and rituximab (P = 00071), but not by secukinumab
(P = 00663). On both mRNA and protein levels, adalimumab, infliximab and
prednisolone reduced the levels of a broader mix of individual cytokines than
secukinumab, ustekinumab and rituximab. Moreover, a significant inhibitory effect
on mRNA expression levels of inflammatory markers in healthy control skin was
observed only for TNF-a inhibitors (P < 0001) and prednisolone (P = 00015).
Conclusions This ex vivo study suggests that TNF-a inhibitors and prednisolone are
the most powerful inhibitors of proinflammatory cytokines and AMPs in HS
lesional skin, which concurs with our clinical experience in patients with HS.
What’s already known about this topic?
• A key element of hidradenitis suppurativa (HS) is an aberrant immune response
characterized by the overexpression of several proinflammatory cytokines and
antimicrobial peptides in lesional skin.
• Biologics targeting inflammatory cytokines have the potential to improve HS dis-
ease activity.
• There is still need for efficacious drugs in the treatment of HS.
What does this study add?
• We sought to quantify the anti-inflammatory effects of currently available biologics
in an ex vivo disease model.
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• Adalimumab, infliximab, secukinumab, ustekinumab and rituximab in addition to
prednisolone significantly inhibited a selected panel of proinflammatory cytokines
and antimicrobial peptides in ex vivo HS lesional skin.
• Adalimumab, infliximab and prednisolone reduced the levels of a broader mix of
individual cytokines than secukinumab, ustekinumab and rituximab.
What is the translational message?
• The significant inhibition of important proinflammatory cytokines by tumour
necrosis factor-a inhibitors in HS correlates with their clinical efficacy.
• Our ex vivo skin culture system represents an adequate model for studies in search
of novel candidate drugs for the treatment of HS and to personalize the treatment
in specific patients.
Hidradenitis suppurativa (HS) is a chronic skin disease charac-
terized by painful, deep-seated, inflamed nodules, abscesses
and, in later stages, sinus tracts.1 Occlusion of the hair follicle
with subsequent rupture, followed by a fierce local inflamma-
tory response, are considered primary pathogenic events. The
aberrant innate immune response involves the upregulation of
various proinflammatory cytokines and antimicrobial peptides
(AMPs).2
Several studies have found elevated mRNA and protein
levels of tumour necrosis factor (TNF)-a in lesional and per-
ilesional HS skin.3,4 Targeting TNF-a with adalimumab and
infliximab has been shown to be clinically efficacious in HS in
randomized placebo-controlled trials.5–7 In addition, the
upregulation of interleukin (IL)-1b, IL-17A and IL-23 in HS
lesions points to the importance of the IL-17 pathway in the
pathophysiology of HS.8–10 Targeting IL-1 in HS yielded
ambiguous clinical outcomes. In a randomized controlled trial
anakinra proved to be efficacious in moderate-to-severe HS,
yet cases of failure for patients on anakinra therapy have been
reported.11–13
Most recently, IL-17 has been targeted in two clinical trials
in HS (NCT02421172, NCT03248531), but the results have
not yet been released. Treatment with secukinumab or ustek-
inumab induced amelioration of HS in a few cases and case
series.14–16 In addition, enhanced levels of AMPs in lesional
HS skin have been described for S100A7 (psoriasin), S100A8,
S100A9, human b-defensin (hBD)-2, hBD-3 and LL-37.17–19
Upregulation of these AMPs in HS lesional skin is mainly dri-
ven by IL-17.18
Chronic HS lesions are characterized by a marked increase
in the number of CD20+, CD79A+ B cells and CD138+ plasma
cells.20 One case report described a clear improvement in HS
after treatment with rituximab for concomitant idiopathic car-
potarsal osteolysis syndrome.21 This highlights the contribu-
tion of these B cells and plasma cells to the inflammatory
process in HS.
Although biologics targeting inflammatory mediators are
now widely used for the treatment of HS, their clinical
efficacy shows great interpatient variability. Our ex vivo skin
culture system is a fast and simple method to investigate and
simultaneously compare the effect of biologics in fresh,
human, lesional HS skin samples.22 It approaches the in vivo
situation by maintaining the patients’ skin architecture and
allows close monitoring of the events following response to
immunostimulators or suppressors in the same experiment.23
Therefore, this study sought to investigate the anti-inflamma-
tory potency of a selection of currently available biologics and
prednisolone for the treatment of HS in an ex vivo skin culture
system using lesional HS biopsies.
Materials and methods
Ethics and informed consent
HS lesional skin was collected from excised skin after HS sur-
gery at the Department of Dermatology of the Erasmus
University Medical Center in Rotterdam, the Netherlands,
from October 2017 to February 2018. According to the opt-
out principle used in the Erasmus University Medical Center
no informed consent is required for the use of excised tissue
for research purposes as this is considered waste material.
Control skin samples were obtained from healthy individuals
in the Sint Franciscus Hospital in Rotterdam, the Netherlands.
All healthy volunteers provided written informed consent for
the use of their excised skin in this study.
Patients with hidradenitis suppurativa
A total of 10 patients with HS (five men and five women)
who had chronic, active disease (seven Hurley stage II,
three Hurley stage III) requiring surgical excision under
general or sedative anaesthesia were included. HS lesional
skin samples were obtained from the inguinogenital area in
five of these 10 patients, from the axillae in four patients
and from the gluteal area in one patient. The mean age
was 437  74 years (SD), the mean body mass index
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(BMI) was 303  65 kg m2, and seven of 10 patients
were current smokers. Eight patients received a stable (≥ 28
days) dosage of systemic antibiotics for their HS at the time
of surgery (four patients used azithromycin 500 mg three
times per week; two patients moxifloxacin 400 mg once
daily, rifampicin 600 mg once daily, and metronidazole
500 mg once daily; one patient clindamycin 300 mg twice
daily, rifampicin 600 mg once daily and metronidazole 500
mg once daily; one patient doxycycline 100 mg once
daily). None of the patients had been using immunosup-
pressive or immunomodulatory therapies including biologics
for at least 2 months prior to surgery.
Healthy control skin
Healthy skin samples were obtained from the submammary
and abdominal waste material of five women who underwent
breast or abdominal reduction surgery. We argue that skin
from these regions is suitable as a control sample because the
inframammary and abdominal folds are predilection sites for
HS. The controls (all female, mean age 410  107 years,
mean BMI 298  42 kg m2, no current smokers) were
otherwise healthy, had no family history of HS, and were not
using any immunosuppressive or immunomodulatory treat-
ment at the time of surgery.
Biopsy procedure
A total of seven fresh 4-mm punch biopsies were taken
per participant. HS skin biopsies were obtained from the
same palpable actively inflamed lesion/infiltrate, and at least
1 cm away from the excision border. Abscesses were not
biopsied in order to avoid sampling only the roof of the
abscess. Each biopsy was weighed prior to culture as
described in an earlier publication.4 HS biopsies had a
mean weight of 24  66 mg, which was significantly
heavier than biopsies from healthy skin with a mean
weight of 161  30 mg (P < 0001). This potential con-
founder was addressed by normalizing all protein levels for
the mg tissue weight.
Ex vivo skin culture
The 4-mm biopsies were immediately cultured in a transwell
system (Netwell; Costar, Cambridge, MA, U.S.A.) as
described previously.22,23 In brief, samples were placed in
punched-out holes in the transwell membrane of a 12-well
plate with the epidermis exposed to the air and the dermis
immersed in 1 mL Iscove’s modified Dulbecco’s medium
(Gibco, Paisley, U.K.) containing 05% human AB serum,
penicillin (100 U mL1) and streptomycin (100 U mL1)
with or without an anti-inflammatory agent. Biologics and
prednisolone were separately added to the culture media
resulting in the following seven conditions: (i) culture media
as negative control; (ii) prednisolone 100 lg mL1 as posi-
tive control; (iii) adalimumab 30 lg mL1; (iv) infliximab
20 lg mL1; (v) secukinumab 30 lg mL1; (vi) ustek-
inumab 10 lg mL1 and (vii) rituximab 200 lg mL1. The
concentrations of the monoclonal antibodies were derived
from the reported trough levels – at least twofold – in
patients with plaque psoriasis (adalimumab,24,25 infliximab,25
ustekinumab,26 secukinumab),27 and CD20+ B-cell malignan-
cies (rituximab).28 Our previous experiments using the
ex vivo model showed that the cytokine concentrations mea-
sured in HS samples were usually in the picogram range.4,7
The biologic concentrations used in our experiments were at
least 1000-fold higher and should suffice for neutralization
purposes. Skin biopsies were incubated for 24 h at 37 °C in
an atmosphere of 5% CO2 and 98% humidity. Subsequently,
the biopsies were placed in 250 lL lysis buffer containing
1% b-mercaptoethanol. Both the supernatants and the biop-
sies were transferred to a polypropylene tube and stored at
20 °C until further analysis.
Messenger RNA expression analysis
Total mRNA was extracted using the GenElute Mammalian
Total RNA Miniprep Kit (Sigma-Aldrich, St. Louis, MA,
U.S.A.). RNA was treated with 01 U lL1 DNAse (Invitrogen,
Carlsbad, CA, U.S.A.) and cDNA was subsequently synthesized
using 1 lg total RNA template, with SuperScript II reverse
transcriptase, random hexamer primers (Invitrogen) and oligo
(dT)15 (Promega Co., Madison, WI, U.S.A.). Primers and
probes were designed and chosen using ProbeFinder Sofware
and the Universal Probe library (Roche Applied Science, Indi-
anapolis, IN, U.S.A.). ABL1 was chosen as a reference house-
keeping gene.29 Real-time quantitative polymerase chain
reaction (qPCR) was performed for the following 12 genes
using the ViiA7 sequence-detection system (Applied Biosys-
tems, Waltham, MA, U.S.A.): TNF-a, IL-1b, IL-6, CXCL-8 (IL-
8), IL-12p19, IL-17A, interferon (IFN)a/MxA, S100A7, S100A8,
S100A9, LL37 and HBD-2. Messenger RNA expression was anal-
ysed with QuantStudio real-time qPCR software version 13
(Applied Biosystems).
Protein quantification
The following 18 inflammation-related cytokines were simul-
taneously measured in the supernatant using a customized
bead-based multi-analyte profiling assay (Luminex, R&D sys-
tems, Minneapolis, MN, U.S.A.): CCL-20, TNF-a, IFNc, IL-1b,
IL-1R1, IL-5, IL-6, IL-10, IL-12/23p40, IL-17A, IL-17E, IL-
18, IL-19, IL-22, IL-27, IL-31, IL-33 and IL-36b. Assays were
used according to the manufacturers’ protocol. A dilution fac-
tor of two was used for all supernatants.
Statistical analyses
The relative mRNA expression and protein production per
sample compared with culture media (negative control) was
calculated for every condition. Protein levels were normalized
according to input weight and expressed in pg mL1 per mg
© 2019 The Authors. British Journal of Dermatology
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tissue weight. The lower limit of quantification was imputed
when protein concentrations in the supernatant (pg mL1)
were below the limit of detection. The Kruskal–Wallis test, i.e.
a one-way ANOVA on ranks, was used to compare the variance
in mRNA and protein levels per inflammatory marker. If one
condition stochastically dominated another condition, the
Dunnett’s post-test was subsequently used to test conditions
vs. culture media (pairwise comparisons) separately. This
approach was chosen in order to increase power. A two-sided
P-value < 005 was considered significant. The level of
significance for the relative mRNA expression and protein
production was separately adjusted by the Benjamini–
Hochberg procedure for multiple comparisons. A correlation
between relative mRNA and protein levels per cytokine was
calculated using the Spearman’s rho test for non-normally
distributed continuous variables. GraphPad Prism version 6
(GraphPad Software, La Jolla, CA, U.S.A.) was used for all
statistical analyses.
Results
Sample flow for analysis
In total, samples from 10 patients with HS and five healthy
controls were analysed by real-time qPCR. Supernatants from
one patient with HS were excluded from multiplex assay
because of erroneous sample processing, resulting in samples
from nine patients with HS with protein data. For control
skin, supernatants of three healthy volunteers were analysed
by Luminex assay. However, protein levels were below the
level of detection or in the very low range of the calibra-
tion line in these control samples (data not shown). There-
fore, samples of the other two healthy volunteers were not
analysed.
Significant downregulation of mRNA expression of
cytokines and antimicrobial peptides by prednisolone
and different biologics
The relative changes in mRNA expression of the 12 genes in the
HS samples, including significance levels, are shown in Table 1.
The overall median inhibitory effect on the mix of cytokines
and AMPs per condition was as follows: prednisolone 057
[interquartile range (IQR) 034–103], adalimumab 051
(033–092), infliximab 053 (032–078), secukinumab
056 (029–099), ustekinumab 064 (044–100) and rituximab
073 (050–119). The inhibitory impact on AMPs was stronger
for the biologics than for prednisolone (Table 1, Fig. 1). Pred-
nisolone, adalimumab and infliximab significantly inhibited
IL-1bmRNA expression. Expression of CXCL-8 (IL-8) was signifi-
cantly downregulated by adalimumab, infliximab, secukinumab
and ustekinumab. Messenger RNA levels of two other important
proinflammatory cytokines, TNF-a and IL-23p19, were not sig-
nificantly downregulated by any of the biologics or prednisolone.
Messenger RNA expression of members of the S100 family and
HBD-2 was significantly reduced by adalimumab, infliximab,
secukinumab and ustekinumab (Table 1). In healthy control skin,
prednisolone, adalimumab and infliximab significantly downreg-
ulated mRNA expression of all tested cytokines and AMPs
(Table S1, Fig. S1; see Supporting Information).
Significant ex vivo reduction in tumour necrosis factor-a,
interferon c, interleukin-1b, interleukin-6, and
interleukin-17A protein levels in hidradenitis suppurativa
lesional skin
In total, 18 cytokines were measured in the culture media. Six
cytokines were not detected in the majority of HS samples
throughout all conditions, namely IL-1RI, IL-5, IL-12/23p40,
Fig 1. Anti-inflammatory impact on the relative mRNA expression of the mix of cytokines and antimicrobial peptides (AMPs) in hidradenitis
suppurativa (HS) lesional skin (n = 10). Horizontal bars display the median. Media, culture media; PRED, prednisolone 100 lg mL1; ADA,
adalimumab 30 lg mL1; IFX, infliximab 20 lg mL1; SEC, secukinumab 30 lg mL1; UST, ustekinumab 10 lg mL1; RTX, rituximab 200 lg mL1.
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IL-22, IL-31 and IL-33. Relative changes in protein production
including significance levels for the other 12 cytokines are
shown in Table 2. The overall median effect on cytokines per
condition was as follows: prednisolone 051 (028–064);
adalimumab 078 (054–091); infliximab 070 (049–094);
secukinumab 085 (069–095); ustekinumab 071 (057–
079) and rituximab 081 (070–094). Specifically the release
of TNF-a, IFNc, IL-1b, IL-6 and IL-17A, was significantly
inhibited by all tested drugs with the exception of secuk-
inumab (Fig. 2). In addition, prednisolone significantly inhib-
ited the release of TNF-a, IFNc, IL-1b, IL-6, IL-17A, IL-10
and IL-25/17E. As expected, adalimumab and infliximab
almost completely neutralized TNF-a levels in the supernatants
(Fig. 3). Of note, for the two important cytokines TNF-a and
IL-17A we observed both a strong intrapatient and interpatient
variability among all biologic conditions (Fig. 3).
Great variation in correlation between mRNA expression
and protein production levels in hidradenitis suppurativa
samples
The cytokines IL-1b, IL-6, IL-17A and TNF-a, were measured
by both real-time qPCR and Luminex. There was great varia-
tion in the correlation between mRNA and protein levels of
these individual cytokines (Fig. 4). A high correlation between
mRNA and protein levels was found for IL-17A (r = 086, P <
0001), while the correlation for TNF-a was almost zero (r =
004, P = 07480).
Discussion
In this study, we show that the commercially available bio-
logics, used in daily practice for the treatment of HS (adali-
mumab, infliximab, ustekinumab and rituximab), significantly
inhibited mRNA and protein expression of various cytokines
and AMPs in lesional HS skin, cultured ex vivo for 24 h.
Secukinumab demonstrated significant downregulation of
inflammatory markers in the lesional skin only at the mRNA
level. The anti-inflammatory effect of prednisolone and all
biologics, except secukinumab, was the strongest at the
protein levels of TNF-a, IFNc, IL-1b, IL-6 and IL-17A,
which are important cytokines in the pathogenesis of HS.
Prednisolone and TNF-a inhibitors seemed to be the most
effective in reducing the release of a broader range of proin-
flammatory cytokines and AMPs in lesional HS skin. Only
prednisolone, adalimumab and infliximab had an inhibitory
effect on the mRNA expression levels of inflammatory mark-
ers in healthy control skin (see supporting information).
In patients with moderate-to-severe HS, the strongest evi-
dence has been documented for the anti-TNF agents adali-
mumab and infliximab.5,30–32 Our translational findings
correspond with the observed efficacy of TNF-a inhibitors in
HS in daily practice. In addition, we confirmed the previously
reported decrease of ex vivo IL-1b protein expression after adal-
imumab treatment on the mRNA level.7 As TNF-a is a multi-
functional cytokine with numerous actions, a simultaneous
downregulation of other cytokines, such as IL-6 and cytokines
of the IL-1 family, could also explain the results of the anti-
TNF agents in our study.9,33
Remarkably, secukinumab did not reduce the IL-17 pro-
tein levels in the same way that adalimumab and infliximab
reduced TNF-a protein levels. Unfortunately, IL-12p40 pro-
tein (target of ustekinumab), an important indicator of the
IL-17 pathway, fell below the level of detection in the
Luminex assay. It could be that other cytokines, such as
TNF-a and IL-1b, not being blocked by secukinumab in this
culture system, were still able to induce production of IL-
17. Moreover, levels of IL-17A were in the lower range of
detection in most patients. Another explanation may be that
the anti-IL-17A antibodies used in the Luminex assay detect
a different epitope of IL-17A than that recognized by secuk-
inumab. The lower mRNA expression of S100A7, S100A9,
IL-6 and CXCL-8 could be considered to be the result of
blocking of IL-17A bioactivity by secukinumab. Similarly, at
the mRNA level, ustekinumab exerted its action predomi-
nantly via IL-6, CXCL-8, S100A7 and S100A9, although the
last three markers were nonsignificant after Benjamini–Hoch-
berg correction.
The pan-cytokine inhibitory characteristics of prednisolone
were demonstrated by inhibition of multiple cytokines on
both the mRNA and protein level, which supports the efficacy
of systemic and intralesional corticosteroids for acute HS flares
in clinical practice.34 However, prolonged high-dose systemic
corticosteroids are not recommended as HS rapidly flares after
tapering, especially after a long course.35 Nonetheless, low-
dose systemic prednisolone could be a valuable adjunct ther-
apy for recalcitrant HS.36
Rituximab was the only biologic without a significant inhi-
bitory effect on individual inflammatory mRNA and protein
levels. This is not surprising as B-cell blockade in inflamma-
tory diseases acts via inhibition of antibody production, anti-
gen presentation and indirectly via cytokine reduction.37
Therefore, the presence of the complete immune system is
required for B-cell blockade to be effective. Moreover, HS is
considered primarily a disease of a deficient innate immunity.
On the other hand, chronic HS lesions are full of B cells and
plasma cells, indicating that adaptive humoral immunity is
also activated in longstanding HS.20,38
The impact of biologics on AMP expression has never been
investigated in HS lesional skin. Our findings indicate a poten-
tial supporting role for AMPs in HS pathophysiology as it is
known that AMPs are capable of activating keratinocytes and
attracting innate immune cells to amplify the local immune
response.39 Cytokines produced by innate and adaptive
immune cells, such as TNF-a, IL-17 and IL-12, drive AMP
production in the keratinocytes.40–42 Moreover, AMPs can be
activated by damage- and pathogen-associated molecular pat-
terns after follicle rupture with the release of keratin fibres
and skin commensals in the dermis.
Although it is assumed that levels of mRNA and protein
have a one-to-one correlation, the absence of correlation
between TNF-a mRNA and its protein levels has been
© 2019 The Authors. British Journal of Dermatology
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previously reported.43–45 In addition, other factors such as the
half-life of proteins and the degradation and stability of mRNA
may vary widely.43,46,47
Major strengths of our study are the use of a standardized
ex vivo transwell culture system and weighing each biopsy in
order to normalize all protein levels for mg tissue weight.
Cytokines were evaluated on both mRNA and protein level,
including four cytokines that were assessed for validation pur-
poses. Furthermore, the use of healthy control skin from
regions that are suitable to function as control samples further
increases the validity of our study. Possible limitations include
the relatively small sample size, lack of dose–response relation-
ships, and AMPs that have only been evaluated on the mRNA
level. Moreover, further analysis using staining techniques at
(a) (b)
Fig 3. Interpatient and intrapatient variability demonstrated by fluctuating protein levels of tumour necrosis factor (TNF)-a and interleukin (IL)-
17A (n = 9). (a) TNF-a. Connected dots represent one patient. High intrapatient variability as demonstrated by the fluctuating per-patient protein
levels between conditions. Low interpatient variability was observed for conditions PRED, ADA and IFX. (b) IL-17A. Connected dots represent one
patient. Very high (more than TNF-a) intrapatient variability. Low interpatient variability for was observed for the condition PRED. PRED,
prednisolone 100 lg mL1; ADA, adalimumab 30 lg mL1; IFX, infliximab 20 lg mL1. SEC, secukinumab 30 lg mL1; UST, ustekinumab
10 lg mL1; RTX, rituximab 200 lg mL1.
Fig 2. Anti-inflammatory impact on protein production of all cytokines and five important cytokines as measured by Luminex assay (n = 9).
The important inflammatory cytokines are tumour necrosis factor-a, interferon c, interleukin (IL)-1b, IL-6, IL-17A. A total of 12 data points are
outside the y-axis range. Media, culture media; PRED, prednisolone 100 lg mL1; ADA, adalimumab 30 lg mL1; IFX, infliximab 20 lg mL1;
SEC, secukinumab 30 lg mL1; UST, ustekinumab 10 lg mL1; RTX, rituximab 200 lg mL1.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019) 181, pp314–323
The ex vivo potency of biologics in hidradenitis suppurativa, A.R.J.V. Vossen et al. 321
the cellular level could potentially indicate the effects of the
biologics on the mRNA expression and protein production of
inflammatory markers in different cellular subsets.
In conclusion, prednisolone, adalimumab, infliximab,
secukinumab, ustekinumab and rituximab significantly inhib-
ited the expression of inflammatory cytokines and AMPs in
ex vivo actively inflamed lesional skin of patients with HS. The
ex vivo model will enable studies with combinations of biolog-
ics and the targeting of novel important cytokines, alone or in
combination with low-dose prednisolone.
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